New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
11:32 EDTTHOR, HTWRHeartWare falls, Thoratec rallies after Wells Fargo flips ratings
Heart pump maker HeartWare (HTWR) is sinking and its competitor, Thoratec (THOR), is climbing after Wells Fargo wrote that the high rate of strokes among patients who have used Heartware's HVAD pump is worrisome. In a trial of Heartware's HVAD pump, which is designed to draw blood from the left ventricle and propel it through an outflow graft connected to the patient's ascending aorta, 11.8% of patients who used the device developed strokes, versus just 4.3% of patients who used a similar product made by Thoratec, Wells Fargo wrote in a note to investors, citing interim data. As a result, HeartWare has placed a warning about strokes on the instructions for its HVAD pump. Wells Fargo believes that this warning may curtail sales of HeartWare's device in the U.S., and the firm downgraded the company's stock to Market Perform from Outperform in a note to investors today. Wells Fargo also upgraded Thoratec to Outperform from Market Perform, as it expects the company to benefit from reduced demand for HeartWare's solution. Moreover, Wells predicts that HeartWare will report lower than expected 2013 revenue, while Thoratec is likely to beat 2013 revenue expectations. The firm also believes there is now a greater chance that HeartWare's device will not be approved as a destination therapy. In late morning trading, HeartWare fell $4.18, or 4.67%, to $85.36, while Thoratec climbed $1.91, or 5.46%, to $36.91.
News For HTWR;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:29 EDTHTWR, THORCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
07:26 EDTHTWRHeartWare weakness a buying opportunity, says Canaccord
Subscribe for More Information
April 17, 2015
07:58 EDTTHORThoratec to hold an investor and analyst meeting
Subscribe for More Information
05:35 EDTTHORThoratec announces positive results from ROADMAP study
Thoratec announced results from the ROADMAP Study, or the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference.
April 16, 2015
10:04 EDTTHORHigh option volume stocks
Subscribe for More Information
09:52 EDTHTWR, THORThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTTHOR, HTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 14, 2015
10:03 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
April 11, 2015
14:10 EDTTHOR, HTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
April 10, 2015
08:37 EDTTHOR, HTWRThoratec price target raised to $50 from $45 at Leerink
Subscribe for More Information
April 9, 2015
07:32 EDTHTWRHeartWare receives Health Canada approval for commercialization of assist system
HeartWare announced that it has received approval from Health Canada, the country's federal department responsible for helping Canadians maintain their health, to market the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
April 7, 2015
10:48 EDTTHOR, HTWRLeerink medical supplies & devices analyst has analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use